Sana Biotechnology, Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Sana Biotechnology, Inc. (SANA) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $5.34 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital › APIC, Share-Based Payment Arrangement, Increase for Cost Recognition
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-10
- Sana Biotechnology, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $5.34M, a 19.41% decline year-over-year.
- Sana Biotechnology, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $5.66M, a 19.37% decline year-over-year.
- Sana Biotechnology, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $5.47M, a 49.16% decline year-over-year.
- Sana Biotechnology, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $6.63M, a 41.75% decline year-over-year.
- Sana Biotechnology, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $25.46M, a 32.42% decline from fiscal 2024.
- Sana Biotechnology, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $37.68M, a 6.04% increase from fiscal 2023.
- Sana Biotechnology, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $35.53M, a 7.31% decline from fiscal 2022.
- Sana Biotechnology, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $38.34M, a 71.44% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $5.34M 10-Q · filed 2026-08-10 | $11.00M derived: sum of 2 quarters · filed 2026-08-10 | ||
| 2026-03-31 | $5.66M 10-Q · filed 2026-08-10 | |||
| 2025-12-31 | $25.46M 10-K · filed 2026-03-03 | |||
| 2025-09-30 | $5.47M 10-Q · filed 2025-11-06 | $12.10M derived: sum of 2 quarters · filed 2026-08-10 | $19.13M derived: sum of 3 quarters · filed 2026-08-10 | |
| 2025-06-30 | $6.63M 10-Q · filed 2026-08-10 | $13.65M derived: sum of 2 quarters · filed 2026-08-10 | ||
| 2025-03-31 | $7.02M 10-Q · filed 2026-08-10 | |||
| 2024-12-31 | $37.68M 10-K · filed 2026-03-03 | |||
| 2024-09-30 | $10.77M 10-Q · filed 2025-11-06 | $22.15M derived: sum of 2 quarters · filed 2025-11-06 | $31.24M derived: sum of 3 quarters · filed 2025-11-06 | |
| 2024-06-30 | $11.38M 10-Q · filed 2025-11-06 | $20.47M derived: sum of 2 quarters · filed 2025-11-06 | ||
| 2024-03-31 | $9.09M 10-Q · filed 2025-11-06 | |||
| 2023-12-31 | $35.53M 10-K · filed 2026-03-03 | |||
| 2023-09-30 | $9.00M 10-Q · filed 2024-11-08 | $18.85M derived: sum of 2 quarters · filed 2024-11-08 | $27.60M derived: sum of 3 quarters · filed 2024-11-08 | |
| 2023-06-30 | $9.85M 10-Q · filed 2024-11-08 | $18.60M derived: sum of 2 quarters · filed 2024-11-08 | ||
| 2023-03-31 | $8.75M 10-Q · filed 2024-11-08 | |||
| 2022-12-31 | $38.34M 10-K · filed 2025-03-17 | |||
| 2022-09-30 | $10.08M 10-Q · filed 2023-11-08 | $19.99M derived: sum of 2 quarters · filed 2023-11-08 | $27.75M derived: sum of 3 quarters · filed 2023-11-08 | |
| 2022-06-30 | $9.91M 10-Q · filed 2023-11-08 | $17.67M derived: sum of 2 quarters · filed 2023-11-08 | ||
| 2022-03-31 | $7.75M 10-Q · filed 2023-11-08 | |||
| 2021-12-31 | $22.36M 10-K · filed 2024-02-29 | |||
| 2021-09-30 | $5.95M 10-Q · filed 2022-11-02 | $10.89M derived: sum of 2 quarters · filed 2022-11-02 | $15.05M derived: sum of 3 quarters · filed 2022-11-02 | |
| 2021-06-30 | $4.94M 10-Q · filed 2022-11-02 | $9.10M 10-Q · filed 2021-08-04 | ||
| 2021-03-31 | $4.16M 10-Q · filed 2022-11-02 | |||
| 2020-12-31 | $5.83M 10-K · filed 2023-03-16 | |||
| 2020-09-30 | $1.17M 10-Q · filed 2021-11-08 | $2.28M derived: sum of 2 quarters · filed 2021-11-08 | $3.04M derived: sum of 3 quarters · filed 2021-11-08 | |
| 2020-06-30 | $1.12M 10-Q · filed 2021-11-08 | $1.87M 10-Q · filed 2021-08-04 | ||
| 2020-03-31 | $755.00K 10-Q · filed 2021-11-08 | |||
| 2019-12-31 | $1.50M 10-K · filed 2022-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |